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CITL Chapter 1: Introduction
Background
Diabetes, a condition in which the body has lost the ability to produce, or to cor-
rectly utilize insulin, is the fifth-leading cause of death by disease in the United States.1  
An estimated 20.8 million Americans have diabetes,2  and the American Diabetes 
Association (ADA) reports that in 2002 the direct and indirect costs of the disorder 
totaled more than $132 billion.3 
Because of demographic shifts—changes in population size, age distribution, and ethnic 
diversity, for example—the ADA projects that by 2010 the number of patients with 
diabetes will have risen by 20 percent and associated costs will be $156 billion.3  Even 
more alarming is the fact that these estimates may actually be conservative, given that 
more Americans than ever are struggling with diabetic risk factors such as obesity. 
The outlook for patients with diabetes is improving, however, as better knowledge of 
diabetes provides them a broader array of options. Landmark studies have shown that 
tight management of the disease can prevent many complications, including stroke, 
blindness, heart disease, and death. Further, treatments such as laser eye surgery can help 
control complications after they develop. In addition, an improved understanding of risk 
factors for diabetes has enabled earlier diagnosis, even prevention.4 
Although these advances have resulted in widely cited guidelines to providers, patients 
with diabetes often fail to receive the recommended care; a survey conducted by 
McGlynn in 2004 revealed that physicians complied with diabetic guidelines less than 
half the time.5 This noncompliance results in part from the structure of our health care 
system, which—despite recognition that chronic conditions such as diabetes account for 
the majority of health care costs—is oriented toward treating acute problems.6  Chronic 
conditions require ongoing multidisciplinary care, as opposed to infrequent visits to a 
physician’s office, and they require patient education on self-care—blood-sugar moni-
toring, adherence to dietary recommendations, exercise, and regular foot inspection, for 
example. 
The “chronic care model” and “disease management” are approaches designed to meet 
many of these needs.7  The chronic care model integrates community resources, health 
system organizations, and self-management with the aid of mechanisms such as decision-
support and clinical-information systems (Figure 1-1).8,9  It provides multidisciplinary 
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evidence-based care and gives the patient the education and tools needed for intimate 
involvement in the management of his or her disease.  
Chronic Care Model 8 
Disease management is defined as “a system of coordinated health care interventions and 
communications for populations with conditions in which patient self-care efforts are 
significant.”10 It is rooted in the assumption that care for chronic diseases can be greatly 
improved without the organizational changes required by the chronic care model.7 
Most disease management programs are built around four specific processes concerning 
patients–identification, enrollment, engagement, and retention–which work in concert 
to improve quality of care and outcomes (Figure1-2). In fact, payers, recognizing that 
disease management may help avoid or delay costly complications of chronic diseases, 
have been investing in disease-management programs, many of which only indirectly 
involve physician practices.11   Such programs emphasize the empowerment of patients 
to manage their own care and to use evidence-based guidelines to help them stay as 
healthy as possible.10 
A growing body of literature suggests that diabetes-management programs in par-
ticular need an information technology (IT) backbone in order to be effective. For 
instance, the Health Care Delivery Work Group from the National Institutes of Health’s 
Behavioral Research and Diabetes Conference concluded in 1999 that in order for a 
diabetes-management program to be successful “it is necessary to have a clinical infor-
mation system” to support it.12   The advantages of IT tools include: promoting better 
Figure 
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provider-guideline compliance by presenting recommendations at the point of care; 
helping to identify patients overdue for care and assisting providers to proactively reach 
out to them; enabling patients to manage their own care through education and com-
munication tools that allow them to receive direct feedback; and providing numerous 
other benefits as well. 
Components of Disease Management
Value Proposition and Research Gaps
IT-enabled diabetes management is believed to create value by improving processes of 
care, which reduces the rate of diabetic complications, which in turn produces both cost 
savings and enhanced quality of life. But the literature on cost-benefit and cost-effective-
ness measures of diabetes management has been limited. Shortcomings in the literature 
include brief study durations, a lack of generalizability of results to external settings and 
populations, and failure to account for factors such as identification, enrollment, and 
retention of patients. In a 2004 analysis of the general disease-management literature, the 
Congressional Budget Office reported that there is “insufficient evidence to conclude 
that disease-management programs can generally reduce overall health spending.”13 
Examples of questions unanswered by the current literature include: 
Do short-term improvements result in long-term benefit? By necessity, studies 
reported in the existing literature usually focus on narrow and specific outcomes over 
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short periods of time. The time and money required to conduct a long-term popula-
tion study are not available for most organizations implementing diabetes management. 
When short-term improvements are seen in these studies, they may not be indicators 
of long-term benefit, merely delaying diabetic complications rather than preventing 
them.
How do study results generalize to other settings? The effectiveness of diabetes-
management programs depends in large part on the characteristics of its patients. A 
relatively healthy patient population will suffer fewer complications than a population 
at higher risk and will have less opportunity for improvements in outcomes. Therefore 
results from a study conducted on young patients with diabetes may not apply, for 
example, to an older and less healthy Medicare population. 
What are the total costs of the programs? Many studies fail to provide any cost 
data. Others report some costs but fail to include measures such as the cost of the inter-
vention itself or of identifying eligible patients. Without a full accounting of all the costs 
of diabetes management, cost-benefit analyses will paint an overly rosy picture. 
Are all eligible patients identified and enrolled in the program? Studies con-
ducted in controlled environments may fail to account for problems associated with 
the identification and enrollment of patients with diabetes in real-world situations. 
Failure to efficiently identify and enroll all eligible patients—typically, because of tight 
constraints on time and money—may result in some patients not receiving the benefit 
of management. Such omissions reduce the economic benefits that the program might 
have realized.
What happens to benefits when the patient changes programs? Because diabetic 
complications are slow to develop, continuity of care is critical to the success of disease 
management; it may take years of tight control for a patient with diabetes to avoid 
complications such as a heart attack or blindness. When patients choose or are forced 
to change health plans or providers, and are obliged to leave a diabetes-management 
program prematurely, they may not have had time to change the course of their disease 
and reap the benefits of management. 
Does an IT-enabled diabetes management program make sense for smaller 
provider organizations? Because small-group practices deliver a substantial fraction of 
chronic care, disease management in those venues can substantially improve the health 
of patients with diabetes. However, because small practices may not be able to realize 
the benefits of economies of scale, their costs of implementing diabetes-management 
programs may be prohibitive. A thorough understanding of the cost considerations of 
alternate approaches to IT-enabled diabetes management will allow practices of all sizes 
to make informed decisions regarding the net value of such programs. 
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Does it make sense for payers? IT-enabled diabetes management may provide pay-
ers with substantial savings from avoided health-care-utilization costs. However, prema-
ture health-plan switching by patients may prevent payers from realizing these savings. 
Further, payers are limited in their management options. Unlike providers, they cannot 
prescribe medications directly; they can only encourage providers and empower patients 
to make the best decisions. 
What are the technology options? In choosing an IT-enabled diabetes-manage-
ment program to implement, today stakeholders are faced with a multitude of options. 
Confusion results from the lack of comparative-benefit studies, without which an intel-
ligent choice is reduced to mere guesswork.  
In this report, the Center for Information Technology Leadership (CITL) has 
addressed these and other outstanding questions with regard to IT-enabled diabetes 
management. 
5Chapter 1: Introduction
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Introduction
IT-enabled diabetes management (ITDM) helps to improve diabetic-care processes, 
which in turn reduces the rate of diabetic complications, thereby generating clinical and 
economic benefit (Figure 2-1). For instance, ITDM promotes strict dietary compliance, 
which improves blood-sugar levels and lessens damage to small blood vessels throughout 
the body. This reduction in microvascular disease lowers rates of diabetes complica-
tions such as blindness, lower-extremity amputations, and end-stage renal disease. Such 
outcomes not only improve patients’ quality of life but also reduce utilization of health 
care resources, potentially leading to cost savings. We have thus focused our analysis on 
savings that result from improved care and reductions in complications, specifically for 
patients with Type 2 diabetes.
Improvements Lead to a Reduction in Complications (adapted from CBO Report 13)
CITL convened a highly qualified expert panel of nationally recognized experts who 
were interviewed by phone using a structured set of questions, participated in a one-
day roundtable discussion, and were consulted throughout the project. The members of 
that panel included:
•	 Madhu	Agarwal,	MD,	Acting	Deputy	Chief	Officer	of	Patient	Care	Services,	Veterans	
Administration
•	 Brian	Austin,	Deputy	Director,	The	Improving	Chronic	Illness	Care	Program,	Group	
Health Cooperative, Seattle
•	 Stephen	 J.	 Brown,	 President	 and	 CEO,	 Health	 Hero	 Network,	 Redwood	 City,	
Calif.
•	 Lawrence	P.	Casalino,	MD,	PhD,	Assistant	Professor,	University	of	Chicago
2 Approach to the Analysis
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•	 Timothy	 G.	 Ferris,	 MD,	 MPH,	 Partners/MGH	 Institute	 for	 Health	 Policy,	
Massachusetts General Hospital, Boston
•	 Jeremy	Grimshaw,	MBChB,	Director,	Centre	for	Best	Practices,	Institute	of	Population	
Health, University of Ottawa
•	 Karen	M.	Kuntz,	ScD,	Associate	Professor,	Harvard	School	of	Public	Health,	Boston
•	 John	A.	Merenich,	MD,	Regional	Director,	Chronic	Disease	Management	Program,	
Colorado Permanente Medical Group, Denver
•	 David	Wennberg,	 MD,	 President	 and	 COO,	 Health	 Dialog	 Analytic	 Solutions,	
Boston
This chapter describes how CITL approached fundamental questions in order to model 
the value of ITDM, estimate costs associated with implementing it, and understand 
how efficiencies influence realization of net benefit. The chapter provides detail on the 
taxonomy that CITL developed for these diabetes-management strategies, the approach 
used to construct the value model, the methodology for determining model inputs, and 
the way in which we determined which process outcomes were to be evaluated. To 
these ends, the sections in this chapter address the following questions:
•	 What	ITDM	technologies	are	available?
•	 How	do	ITDM	technologies	affect	processes	of	care?
•	 How	do	ITDM-influenced	changes	in	processes	of	care	result	in	improved	clinical	
and	economic	outcomes?
•	 What	are	the	costs	of	ITDM	systems?
•	 How	does	patient	participation	affect	the	value	of	ITDM?
•	 How	do	these	costs	and	benefits	apply	to	ITDM	in	a	particular	setting?
•	 How	stable	are	the	ITDM	cost	and	benefit	projections?
Available Technologies: ITDM Taxonomy
To help frame subsequent analysis, CITL derived the following taxonomy of ITDM 
technologies, which is described in detail below: 
•	 Technologies	used	by	payers
•	 Technologies	used	by	providers
o Disease registries
o Clinical decision-support systems
•	 Technologies	used	by	patients
o Self-management
o Remote monitoring
•	 Integrated	provider-patient	systems
Technologies Used by Payers
Payer systems interface with electronic-claims systems to track patients with diabetes 
and monitor diabetic-specific information. Payer systems compare patient data with 
9recommended guidelines in order to identify opportunities for improved management; 
provide feedback to patients and providers by telephone, email, or postal mail; and can 
focus on behavioral change, using health coaches to convey educational and motiva-
tional information to patients. The systems, which may be based at the payer organi-
zations themselves or at separate disease-management companies, involve only those 
two entities and patients. There is typically no point-of-care component, though many 
programs do follow up with providers during or after an intervention.
Technologies Used by Providers
Diabetes registries track patients with diabetes and store information specific to their care. 
At the point of care, registries may generate concise patient reports for clinicians that 
highlight areas for attention during the office visit. Registries may also aggregate infor-
mation across the population to generate “report cards,” which show, for example, the 
proportion of patients with diabetes who had foot exams during the prior six months or 
a list of patients with hemoglobin A1c (HbA1c) levels above 7 percent, which indicates 
that the patient’s blood-sugar level is too high. Registries may also use these report cards 
to facilitate a provider’s communication with patients—for instance, to generate lists for 
announcements about available diabetes-education sessions or to facilitate appointment 
scheduling. 
Clinical decision-support systems (CDSSs) generate alerts and reminders for clinicians dur-
ing a patient visit. Such communications may caution providers about potential errors 
or remind them of recommended guidelines for improving quality of care. In addition, 
CDSSs may offer information that helps providers navigate the complex array of treat-
ment options by suggesting regimens based upon a patient’s condition. Unlike diabetes 
registries, CDSSs are built on electronic medical records (EMRs), which maintain com-
prehensive health data about each patient. Though EMRs are not generally designed for 
population-level reporting, providers and their office staff may query them to generate 
such information.
Technologies Used by Patients
Self-management technologies provide patients with educational resources and data-
gathering mechanisms for managing their own care between provider visits. These 
technologies include automated phone systems that generate reminders or offer edu-
cational content; electronic diary tools that collect information to be taken to a visit; 
interactive educational programs on computers; and online resources, such as peer 
support groups, sponsored by providers. 
Remote-monitoring technologies capture and send providers information that is needed 
to facilitate diabetes management between office visits; patients periodically submit 
structured electronic data about their condition—via a telephone’s touchtone keypad, 
for example—and they receive feedback and instructions. Newer remote-monitoring 
programs use Web sites that accept data uploaded directly from glucometers and other 
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home devices.  Although the focus of remote-monitoring technologies is on the data 
sent from the patients’ homes to providers’ offices, some systems also deliver educational 
content to patients, content such as self-care advice in recorded phone messages, when 
they submit their data. These systems may also connect patients to resources such as 
EMRs, endorsed educational materials, interactive self-care tools, and provider e-mail.
Integrated Provider-Patient Systems
CITL envisions a fully integrated chronic-care platform that would coordinate the 
delivery of evidence-based care across multiple care settings, including outpatient clinics 
and patients’ homes. This system would include a disease registry to manage chronically 
ill populations, patient education tools to support self-management, and remote-moni-
toring devices to measure and report patient symptoms and clinical progress to provid-
ers between visits. Although we could not find an example of such an integrated system, 
we included it in our analysis to show its potential impact.
How Technologies Affect Processes of Care: ITDM Impacts Engine
CITL surveyed the literature to find the best estimates for the impacts that each form 
of ITDM has on Type 2 diabetes care processes. We then created the ITDM Impacts 
Engine to transform reported evidence of physiologic and care-process improvements 
into expected process improvements for new care settings over time.
Data Sources
CITL relied on a variety of sources to estimate the impact of each diabetes-management 
strategy on care processes. We searched academic publications and a wide array of non-
academic literature, including trade journals, government publications, the general press, 
vendor and consultant studies, proprietary research services, and studies by foundations 
and professional associations. Preference was given to evidence published in peer-reviewed 
literature.
For each data element in the model, we chose from the evidence a single best esti-
mate, based on study design strength and closeness of fit to the taxonomy. We applied 
a standardized quality-scoring sheet to each study without regard to the direction or 
magnitude of its result.  
We used data from these studies as inputs into the ITDM Impacts Engine. In certain 
instances, CITL was required to convert some of these data into a format usable by the 
model. Table 2-1 details the final ITDM impact data used in the ITDM Impacts Engine; 
Appendix 1 summarizes the studies from which these inputs were derived.
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Physiologic and Care-Process Improvement Evidence from Literature Review  
and Evidence Synthesis
Blood Glucose Blood Pressure Cholesterol
Eye Exam 
Screening
Foot Exam 
Screening
Microalbumin 
Screening
Pa
ye
r
Payer
HbA1c (%)
8.36 to 8.0214
SBP (mmHg)
132.5 to 128.715
LDL (mg/dl)
114 to 104.615
Rate (%)
40 to 4816
Rate (%)
2 to 2517
Rate (%)
27.3 to 37.316
Pr
ov
id
er
Clinical 
Decision 
Support
Systems
HbA1c (%)
8.4 to 8.1718
SBP (mmHg)
138.1 to 13918
LDL (mg/dl)
126.7 to 11218
Rate (%)
12.2 to 19.319
Rate (%)
46.2 to 55.619
Rate (%)
23.3 to 43.619
Diabetes 
Registries
HbA1c (%)
7.3 to 6.120
SBP (mmHg)
140 to 139.120
LDL (mmol/dl)
3.2 to 2.720
Rate (%)
36 to 6920
Rate (%)
67 to 8820
Rate (%)
27 to 5520
Pa
tie
nt
Remote 
Monitoring
HbA1c (%)
9.5 to 8.621
SBP (mmHg)
141 to 13121
LDL (mg/dl)
100 to 9421
Self- 
management
HbA1c (%)
7.45 to 7.4222
Total Chol:HDL
5.7 to 5.1322
HbA1c = hemoglobin A1c, SBP = systolic blood pressure, LDL = low-density lipoprotein, HDL = high-density lipoprotein
Model Development
Six care-impact measures were chosen for inclusion in the Impacts Engine, based on 
whether they (1) were consistent with diabetes-care guidelines,4 (2) could be incorpo-
rated into the CITL Diabetes Disease-Burden Engine, described below, and (3) could 
be reported across all technologies in the taxonomy. These criteria ensured that the 
resulting impacts would be consistent with scientific knowledge, project both clinical 
and economic benefit in our model, and produce results that were comparable across 
all forms of ITDM in our taxonomy. The resulting measures were changes in HbA1c, 
systolic blood pressure (SBP), and cholesterol levels, as well as the rates of eye exams, 
foot exams, and microalbuminuria screening.
Some outcomes of diabetic-care guidelines, such as pneumococcal vaccinations rates, were 
not included because their clinical impact could not be incorporated into the model. 
Other outcomes, such as emergency-department visits and avoided admissions, were 
not modeled because the impact of ITDM on them was inconsistently reported. Also, 
although we built into our model the ability to incorporate foot-ulcer and amputation 
rates, we did not find evidence in the literature that ITDM affected these outcomes.
How Changes in Processes of Care Result in Improved Clinical and 
Economic Outcomes: ITDM Disease-Burden Engine
The next step in assessing ITDM value was the projection of care-process improve-
ments on clinical outcomes and complications from Type 2 diabetes. To this end, we 
created the Disease-Burden Engine. 
Table 
2-1
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Data Sources
Because many disease-state models have been developed to project the future disease 
burden of diabetes and its complications, we surveyed these models to find one that 
we could reuse and extend. The model had to account for the social, economic, and 
health care environments of the United States. It had to be modifiable, so that it could 
incorporate the effects of ITDM interventions. Finally, it had to be flexible enough to 
handle additional model parameters to address hypotheses of interest.
We chose as a starting point for our Disease-Burden Engine a model created by the 
Centers for Disease Control and Prevention (CDC) in conjunction with the Research 
Triangle Institute (RTI).23,24  This model was developed for the health care environ-
ment in the United States and allowed modifications for measuring the full spectrum 
of IT’s potential alterations of the course of disease. However, the model was based only 
on newly diagnosed diabetics and did not account for the impact of changes in preven-
tive screening rates and other process-of-care improvements. Therefore we extended 
the	CDC/RTI	Diabetes	Cost-Effectiveness	model	to	include	such	effects,	and	we	com-
bined it with another published model to account for the impact of diabetic retinopathy 
screening.25 We also expanded the model to simulate patients with pre-existing diabetes 
and other demographic variations in the patient population. 
Model Development
The resulting Disease-Burden Engine characterizes five complications of diabetes: 
nephropathy, peripheral neuropathy, retinopathy, coronary heart disease (CHD), and 
stroke (Figure 2-2). The Engine specifies various levels of severity for each complication 
and how patients with diabetes may progress through those disease states.  For example, 
in the case of CHD, a patient may progress from normal to angina, suffer a heart attack, 
and ultimately die. 
Combined with the ITDM Impacts Engine, the Disease-Burden Engine predicts the 
degree to which care-process improvements decrease the chance that a patient will 
progress to a more severe disease state. Estimates of such changes were derived from 
the medical literature, consistent with the original CDC model. Where credible medi-
cal evidence was lacking, no benefit was projected. For example, while the landmark 
United	Kingdom	Prospective	Diabetes	Study	reported	that	 improved	glucose	control	
might lower the risk of heart attacks,26 this result just missed statistical significance and 
was therefore not included in the model. 
13
Simplified Schematic of Model Disease States
Costs of the Systems: ITDM Implementation-Cost Engine
CITL created the Implementation-Cost Engine to estimate the expenses involved in 
implementing and operating each form of ITDM. 
Data Sources
Because published cost estimates are not widely available, CITL relied primarily on 
market research for these data. With the help of the Disease Management Association 
of America (DMAA), CITL collected information via structured phone interviews 
with 38 organizations currently implementing ITDM or that sell diabetes-management 
technologies. CITL interviewed at least one and up to sixteen confidential sources for 
each form of ITDM represented in our taxonomy.  
Figure 
2-2
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Model Development
With the exception of Payer ITDM (in which diabetes management is generally 
outsourced), the Implementation-Cost Model was built from the following common 
components:
•	 Identification. Costs incurred for identifying all eligible patients with diabetes from the 
entire pool of patients.
•	 Hardware. Costs incurred for obtaining hardware (e.g., computers) necessary to sup-
port the IT diabetes-management program.
•	 Software. Software-licensing costs, when software must be purchased.  Programmer 
costs, when applications must be developed.
•	 Interfaces. Costs to transform data from external systems into a standard format for the 
diabetes-management application.
•	 IT support staff. Staff costs required specifically for IT components of the management 
program.
•	 Training. Costs to train users of the systems.
•	 Non-IT programmatic costs. Costs incurred to implement diabetes-management pro-
grams that are unrelated to their IT components.
Technologies Used by Payers
For payer technologies, we assumed that the payers identify eligible patients in their 
plans and then hand over diabetes management to an external disease management 
vendor. Thus the Implementation-Cost Engine applies costs to the payers in setting up 
and running claims analyses that identify patients with diabetes, and it applies the costs 
of staff to support the program as well. The Engine then applies program-management 
costs including an implementation fee and a per-intervened-patient-per-month (PIPM) 
cost, wherein many of the cost components are bundled together. This PIPM fee varies 
by size of the intervened population and their insurance status.  
Technologies Used by Providers
For diabetes registries, the Implementation-Cost Engine assumes that practices pur-
chase a registry application from a vendor and run it as an application service provider 
(ASP) model, thus minimizing the requirements for on-site development and support. 
The main cost driver of this approach is the expense of building interfaces to existing 
practice systems. We assumed that providers would require three such interfaces, based 
in part on reports in the literature.27 Additional expenses include the costs of personal 
computers (PCs) for providers to run the application at the point of care, annual license 
fees for software and hosting services, costs of setting up and running claims analysis to 
identify patients with diabetes, and costs of quarterly alerts and reminder mailings to 
patients.
For clinical decision support, the Implementation-Cost Engine focuses on costs associ-
ated with modifying existing EMRs in order to sustain robust diabetes management. 
The main expense, applied as a fixed cost to the organization, is in the time required to 
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develop and implement diabetes guidelines in the EMR. We did not include the costs 
of implementing the original EMRs themselves. Other expenses include the cost of a 
part-time program manager to oversee the effort.
Technologies Used by Patients
For remote monitoring technologies, the Implementation-Cost Engine assumes that 
each patient with diabetes is given a device that connects a glucometer to a telephone 
line and uploads data.  Major cost drivers in this approach are data-transmission devices 
and software-licensing fees for each patient, as well as personal computers, software-
licensing fees, and staff time for registered nurses who monitor and respond to incoming 
data. Additionally, there are the costs to set up and run claims analysis to identify patients 
with diabetes, interface costs for ensuring that practice systems will accept incoming 
data, and training costs for staff and patients.
For self-management technologies, the Implementation-Cost Engine assumes that 
patients are given access to a Website with education modules and customized self-
management tools. The main cost drivers of this approach are PCs for clinical staff 
(dieticians, diabetes educators), staff time dedicated to providing tailored feedback and 
to moderating group forums, and the annual per-patient and per-dietician software fees 
charged by the vendor. Additional costs are those incurred in setting up and running 
claims analysis to identify diabetics, building an interface to the practice system, and 
training staff and patients.
Integrated Provider-Patient Systems
For integrated diabetes-management systems, the Implementation-Cost Engine assumes 
that diabetes registries are extended with remote-monitoring and self-management 
technologies to allow a more comprehensive diabetes-management approach—one that 
fully involves both providers and patients. The cost of this approach is the sum of the 
costs for the diabetes-registry-application, remote-monitoring, and self-management 
platforms. Any double-counted costs, such as identification and interface costs, were 
removed. 
Key Assumptions: Cost Estimates for Components
Several assumptions applied throughout the cost modeling: 
•	 Phone	and	Internet	connectivity	exist	where	needed,	and	these	costs	are	not	included	
in the model.
•	 Hardware	is	replaced	every	five	years.	
•	 Annual	software	maintenance	represents	20	percent	of	acquisition	cost.
•	 Annual	interface	maintenance	represents	17.5	percent	of	acquisition	cost.
•	 Organizations	begin	ITDM	activity	with	no	diabetes-specific	IT	or	disease-management	
intervention already in place.
•	 Economies	of	scale	and	volume	discounts	are	taken	into	account,	where	possible.	
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Costs were normalized to 2004 dollars, using Consumer Price Index data.28 Staff 
costs were calculated as annual fully loaded salaries (base pay plus fringe benefits) and 
then broken down into hourly costs for a 40-hour workweek. Cost estimates for the 
approaches were not intended to account for all of the costs associated with any par-
ticular intervention approach; they were solely meant to capture an average cost associ-
ated with using a particular type of IT. Therefore CITL excluded several costs from the 
model. These included the costs of (1) conversion of legacy data or data cleaning, (2) 
sales or pre-sales activities such as contracting, (3) patient-support technologies such as 
basic glucometers, (4) patient or provider recruitment or marketing, (5) program plan-
ning and development, (6) increases or decreases in time for providers and their staff 
to use the IT and information contained within it, and (7) practice re-engineering. 
For detailed cost assumptions, please refer to Appendix 2: Intervention-Cost-Engine 
Estimates.
How Patient Participation Affects Value: ITDM Population-Selection 
Engine
The potential of diabetes management may be wasted if patients with diabetes are 
not actively identified, enrolled, engaged, and retained in such programs. We therefore 
modeled the effects of “churn”: the entry and subsequent withdrawal of patients from 
IT-enabled diabetes-management programs.
Data Sources
To assess rates for churn, we performed a targeted literature review and conducted 
interviews to estimate rates at which patients move through diabetes-management 
programs. To factor in the rates at which patients with diabetes would be eligible for 
participation in the first place, we extracted diabetes incidence and prevalence rates 
from the 2001-2002 National Health and Nutrition Examination Survey (NHANES) 
dataset.   These incidence and prevalence rates were applied to all patients in the pool of 
patients, without regard to how frequently they are seen by a provider.  Table 2-2 sum-
marizes the various patient turnover rates used by the Population-Selection Engine.
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Annual Rates Used by the Population-Selection Engine 
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% of Patients Retained 95%29 93%30, 31 93%30, 31 93%30, 31 93%30, 31 93%30, 31
Diabetes Incidence 1.42% 1.42% 1.42% 1.42% 1.42% 1.42%
Diabetes Prevalence 11.5% 11.5% 11.5% 11.5% 11.5% 11.5%
% Successfully Identified for 
ITDM Program
93%32 93%32 93%32 91%33 91%33 93%32
% of Identified Patients 
Enrolled in ITDM Program
95%16, 34 100%* 100%* 18%21 60%35 100%*
% of Enrolled Patients 
Retained in ITDM Program
98%36 100%* 100%* 98%21 88%37 100%*
* Physician participation rate assumed to be 100%.
Model Development
Building and maintaining participation in diabetes-management programs involve sev-
eral steps. Eligible patients must first be identified and invited to participate. However, 
enrollment into the program does not guarantee continued participation. Patients with 
diabetes may leave the program directly, or they may leave the provider panel or payer 
plan and no longer be eligible. This exit phenomenon is offset by new patients with 
diabetes entering provider panels and payer plans, and by non-diabetic member patients 
who may develop diabetes over time. We created the Population-Selection Engine 
to account for such factors. The Engine assumes that provider panels and payer plans 
remain at a constant size on average, and the number of annual new members is calcu-
lated accordingly. 
How Costs and Benefits Apply to Different Settings: ITDM Net-Benefit 
Projection Engine
CITL created the Net-Benefit Projection Engine to apply the above engines to 
specific settings. The potential of ITDM to improve the health status of populations 
depends not only on the characteristics of the technologies but also on those of the 
population and care environments. For instance, populations with higher prevalence 
Table 
2-2
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rates of diabetes or with higher disease severity may have the potential to benefit 
more from ITDM. In any case, the model was designed to project the value of ITDM 
for any population, as defined by a set of key demographics and average health status 
of patients with diabetes. 
Data Sources
Data from the U.S. Census and Centers for Medicare and Medicaid Services, among 
others, were used to create the distribution of payer panels.38-43  Data from the 
American Medical Association (AMA) and Community Tracking Study Physician 
Survey were used to create the distribution of provider practices. We derived national 
averages for diabetic-population characteristics from the 2000 Census and 2001-2002 
NHANES.44 
Model Development
The Net-Benefit Projection Engine characterizes the distributions of providers and 
patients in organizations of various sizes. The Engine also describes the distribution of 
those organizations in order to aggregate the net benefit into a national figure. To be 
consistent with the CDC-RTI model, CITL eliminated all diabetes patients younger 
than age 25.
CITL split the national payer scenario into four arms: Medicaid Managed Care, Medicaid 
Fee-for-Service, Medicare Fee-for-Service, and a Payer Mix group that included both 
Medicare Managed Care and commercial insurers. To avoid double counting, individu-
als eligible both for Medicare and Medicaid were assigned to Medicare if they were age 
65 or older and to Medicaid if they were younger than 65. Uninsured individuals and 
those covered by military health or consumer-directed health plans were excluded. 
For provider-level analyses, CITL used AMA data to estimate the number of patients 
from the number of full-time specialist and primary-care providers who would treat 
diabetes.45 We then applied age and gender adjustments46 to account for part-time pro-
viders. To determine the distribution of diabetes-care providers by practice size, CITL 
used estimates of all primary-care physicians by practice size (extracted from the 2000-
2001 Community Tracking Survey47) and then scaled those estimates by the percentage 
of providers who treat patients with diabetes.45
U.S. Census data were used to characterize the basic demographics of the general popu-
lation as well as the population of each of the four insurance pools. On the basis of 
these demographics, which included age, gender, and ethnicity, the health status of an 
individual was projected. Health-status information included basic physiological param-
eters, such as systolic blood pressure, hemoglobin A1c, and cholesterol ratio, as well as 
prevalence of pre-existing co-morbidities such as heart attack, blindness, and stroke.
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Sensitivity Analysis and Stability Testing
In CITL’s ITDM Model, we defined specific disease states for patients with diabetes, 
such as having angina, and determined the probability of progressing to new disease 
states, such as having a cardiac arrest. Because it was impractical to analyze, one by 
one, all possible outcomes for all possible combinations of starting demographics and 
health statuses, the model was run as a Monte Carlo simulation. That is, a starting set of 
demographics and health statuses was randomly chosen, and the progressions for that 
simulated patient set was tracked and recorded. This process was repeated hundreds of 
thousands of times, in each run of the model, to estimate the outcomes for a particular 
population of patients. Because these simulation outcomes are not absolute, the model 
was run several times to test the stability of results. Such testing showed that the financial 
results varied by less than one percent between runs.
Key	model	 inputs	 were	 also	 tested	 through	 a	 series	 of	 one-way	 sensitivity	 analyses.	
These variables included ITDM impact estimates used by the Intervention-Impacts 
Engine, patient-turnover rates used by the Population-Selection Engine, and discount 
rates used across the model. Model runs were conducted with values for key variables 
changed to reasonably high and low limits, as gleaned from our evidence collection 
process. Where no limits were discovered in the evidence, variables were increased and 
decreased by 25 percent. 
Approach-to-Analysis Summary
The current literature does not include the long-term benefits of ITDM, and without 
such analysis it is difficult for organizations to make decisions on whether to invest 
and what kind of technology to invest in. CITL’s five-engine model addresses these 
issues. The model was developed to allow for the input of various ITDM technologies, 
patient-population characteristics, features of health care organizations, and attributes 
of the U.S. health care system as a whole. The interaction of these inputs and model 
engines can be seen in Figure 2-3. 
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ITDM Model Overview To fully appreciate the importance of each component of the CITL ITDM model, it 
is helpful to return to the questions and limitations listed earlier in the introduction 
to this report.
Do short-term changes using ITDM project out to long-term 
benefit? 
The ITDM Impacts Engine applies best available evidence to the Disease-Burden 
Engine to show how process improvements can gradually alter the course of disease.
How do study results using ITDM generalize to other settings?
By applying specific demographic, epidemiologic, and organization data to the 
Disease-Burden Engine, Implementation-Cost Engine, and Net-Benefits Projection 
Engine, the value of ITDM can be estimated for different organizations and the 
nation.
What is the total cost of an ITDM system?
The Implementation-Cost Engine provides a comprehensive estimate of costs asso-
ciated with implementation of ITDM, excluding certain costs as assumed (EMR, 
connectivity).  Both cost of routine care and cost of diabetic complications are incor-
porated into the Disease-Burden Engine.
Are all eligible patients identified and enrolled in ITDM programs?
The Population-Selection Engine dilutes the potential value of ITDM by taking into 
account how successful programs are in identifying and enrolling diabetics into the 
program.
What happens to benefits when the patient changes ITDM 
programs?
The Population-Selection Engine accounts for patients with diabetes leaving and 
entering the program, and existing patients developing new-onset diabetes.
Does ITDM make sense for smaller organizations?
The Net-Benefits Projection Engine combines the estimated benefits with costs from 
the Implementation-Cost Engine to illustrate how economies of scale may operate 
with regard to ITDM.
Does ITDM make sense for the payers?
The Net-Benefits Projection Engine addresses the complete cost and benefit picture 
to show how ITDM may benefit payers as well as providers.
What are the ITDM technology options?  
The ITDM taxonomy organizes the technology options into a framework that facili-
tates analysis, and the ITDM impact engine shows how various forms of ITDM may 
impact processes of care.
Figure 
2-3
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is helpful to return to the questions and limitations listed earlier in the introduction 
to this report.
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What is the total cost of an ITDM system?
The Implementation-Cost Engine provides a comprehensive estimate of costs asso-
ciated with implementation of ITDM, excluding certain costs as assumed (EMR, 
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porated into the Disease-Burden Engine.
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The Population-Selection Engine dilutes the potential value of ITDM by taking into 
account how successful programs are in identifying and enrolling diabetics into the 
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What happens to benefits when the patient changes ITDM 
programs?
The Population-Selection Engine accounts for patients with diabetes leaving and 
entering the program, and existing patients developing new-onset diabetes.
Does ITDM make sense for smaller organizations?
The Net-Benefits Projection Engine combines the estimated benefits with costs from 
the Implementation-Cost Engine to illustrate how economies of scale may operate 
with regard to ITDM.
Does ITDM make sense for the payers?
The Net-Benefits Projection Engine addresses the complete cost and benefit picture 
to show how ITDM may benefit payers as well as providers.
What are the ITDM technology options?  
The ITDM taxonomy organizes the technology options into a framework that facili-
tates analysis, and the ITDM impact engine shows how various forms of ITDM may 
impact processes of care.
Chapter 2: Approach to the Analysis

23
CITL Chapter 3: Results
Common Assumptions
The model projected the value of each form of ITDM separately—combinations of 
two or more forms of ITDM were excluded from our analysis—and the results that 
follow reflect the impact of its full national adoption. We assumed that ITDM would 
be deployed uniformly over a five-year period, so that each year another 20 percent of 
all organizations would come on board. All diagnosed and insured patients with Type 2 
diabetes older than age 25 were included in the analysis.
We assumed that the full impact of ITDM on process of care would be achieved in 
the first year of implementation, given that each of the contributing studies reported 
impact within 12 months. We also assumed that this impact remained constant over the 
ten years considered in this analysis, as long as a patient remained in the diabetes-man-
agement program. The costs of care for patients with diabetes were derived from the 
original CDC model and updated to reflect changes in standards of care. All financial 
values were calculated on a present-value basis, using a five percent discount rate.
Technologies Used by Payers
Payer interventions commonly include an integrated set of IT tools that enable tar-
geted telephone-, Web-, and mail-based management of a diabetic population along 
with communication with these patients’ providers. The main IT component of such 
diabetes-management programs is an in-house payer- or vendor-owned diabetes-reg-
istry software application. These systems interface with claims-based and select clinical 
data to update and integrate patient information. Diabetes-management programs may 
monitor diabetic outcomes, process measures, and values against accepted standards and 
recommended guidelines in order to provide feedback to patients and providers.
Patient Participation: Participation in payer programs would be relatively high. While 
some patients with diabetes might choose not to participate in diabetes management 
by payers, enrollment and retention rates would generally be far higher than in remote-
monitoring and self-management programs.  
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Care Process: When fully implemented, national adoption of payer technologies 
would improve average:
•	 Retinopathy	screening	from	14	percent	to	26	percent
•	 Peripheral	neuropathy	screening	from	45	percent	to	58	percent
•	 Microalbuminuria	screening	from	45	percent	to	53	percent.
Physiology: When fully implemented, national adoption of payer technologies would 
improve average:
•	 Hemoglobin	A1c	(HbA1c)	by	0.24	percent	
•	 Systolic	blood	pressure	(SBP)	by	5.4	mmHg
•	 Cholesterol	by	11	mg/dl.
Clinical Outcomes: Over the first ten years, national adoption of payer technologies 
would cumulatively reduce:
•	 Heart	attacks	by	54,000
•	 Strokes	by	19,000
•	 Kidney	failure	by	3,000
•	 Amputations	by	190,000
•	 Blindness	by	18,000
•	 Diabetes-related	mortality	by	380,000.
Financial Outcomes: Over the first ten years, the national rollout of payer technolo-
gies would result in:
•	 Implementation	cost	of	$21.6	billion
•	 Cost-of-care	savings	of	$7.1	billion
•	 Overall	net	cost	of	$14.5	billion.
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Technologies Used by Providers
Diabetes Registries
Diabetes registries improve diabetic care in a number of ways. Through reminders at 
the point of care, registries can assist clinicians in making decisions that comply with 
diabetic guidelines. Through tools such as report cards, registries provide an opportunity 
for clinicians to identify potential for improvement across the panel of patients. Through 
mailed reminders to patients, registries can help heighten compliance and empower 
patients to be active participants in their own care.
Patient Participation: Participation in diabetes registries would be relatively high, as 
enrollment is typically automatic, and patients tend not to opt out. The primary source 
of patient non-participation would be failure by the management program to identify 
eligible candidates for enrollment. 
Care Process: When fully implemented, national adoption of diabetes registries would 
improve average:
•	 Retinopathy	screening	from	14	percent	to	62	percent
•	 Peripheral	neuropathy	screening	from	45	percent	to	80	percent
•	 Microalbuminuria	screening	from	45	percent	to	66	percent.
Physiology: When fully implemented, national adoption of diabetes registries would 
improve average:
•	 HbA1c	by	0.50	percent	
•	 SBP	by	1.1	mmHg
•	 Total	cholesterol	by	31	mg/dl.
Clinical Outcomes: Over the first ten years, national adoption of diabetes registries 
would cumulatively reduce:
•	 Heart	attacks	by	100,000
•	 Strokes	by	5,200
•	 Kidney	failure	by	5,600
•	 Amputations	by	560,000
•	 Blindness	by	63,000
•	 Diabetes-related	mortality	by	710,000.
Financial Outcomes: Over the first ten years, the national rollout of diabetes registries 
would result in:
•	 Implementation	cost	of	$6.16	billion
•	 Cost-of-care	savings	of	$14.5	billion
•	 Net	cost	savings	of	$8.34	billion.
Chapter 3: Results
26 The Value of Information Technology-Enabled Diabetes Management
Clinical Decision-Support Systems
Clinical decision-support systems are a powerful aid to clinicians at the point of care. 
By combining patient information with the latest medical knowledge, they offer rec-
ommendations to clinicians for optimal individualized care. Physicians can use these 
recommendations to improve control of blood sugars and other physiologic parameters 
as well as to improve compliance with screening and other care-process guidelines.
Patient Participation: Participation in CDSS would be relatively high, as patients gen-
erally do not choose to opt out. The primary source of patient non-participation would 
be failure by the management program to identify eligible candidates for enrollment. 
Care Process: When fully implemented, national adoption of CDSS would improve 
average:
•	 Retinopathy	screening	from	14	percent	to	24	percent
•	 Peripheral	neuropathy	screening	from	45	percent	to	68	percent
•	 Microalbuminuria	screening	from	45	percent	to	61	percent.
Physiology: When fully implemented, national adoption of CDSS would improve 
average:
•	 HbA1c	by	0.28	percent	
•	 Increase	in	SBP	by	4.0	mmHg.
•	 Total	cholesterol	by	4.5	mg/dl
Clinical Outcomes: Over the first ten years, national adoption of CDSS would 
cumulatively:
•	 Increase	strokes	by	12,000	(This	result	likely	reflects	the	projected	increase	in	blood	
pressure. See discussion section.)
•	 Reduce	kidney	failure	by	2,600
•	 Reduce	amputation	by	340,000
•	 Reduce	blindness	by	20,000
•	 Reduce	diabetes-related	mortality	by	210,000.	
It would have no statistically significant effect on heart attacks (at α=0.05).
Financial Outcomes: Over the first ten years, the national rollout of clinical decision 
support would result in:
•	 Implementation	costs	of	$19.3	billion
•	 Cost-of-care	savings	of	$10.7	billion
•	 Overall	net	cost	of	$8.6	billion.
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Technologies Used by Patients
Remote Monitoring
Remote-monitoring technologies allow clinicians to gauge the degree of control of a 
patient’s diabetes between visits and to modify care plans accordingly. These technolo-
gies offer the potential to improve blood glucose, blood pressure, and cholesterol, for 
example. 
Patient Participation: Participation in remote monitoring would be low. Many 
patients would choose not to enroll or to drop out after enrollment. 
Care Process: When fully implemented, national adoption of remote monitoring 
technologies would have no statistically significant impact on provider decisions to 
screen for retinopathy, neuropathy, or microalbuminuria. 
Physiology: When fully implemented, national adoption of remote-monitoring tech-
nologies would improve average:
•	 HbA1c	by	0.03	percent
•	 SBP	by	0.56	mmHg
•	 Total	cholesterol	by	2.8	mg/dl.
Clinical Outcomes: Over the first ten years, national adoption of remote-monitoring 
technologies would cumulatively reduce:
•	 Heart	attacks	by	12,000
•	 Diabetes-related	mortality	by	270,000.
It would have no statistically significant effect on strokes, kidney failure, amputations, or 
blindness (at α=0.05).
Financial Outcomes: Over the first ten years, the national rollout of remote-monitor-
ing technologies would result in:
•	 Implementation	costs	of	$6.83	billion
•	 Cost-of-care	savings	of	$326	million
•	 Overall	net	cost	of	$6.5	billion.
Self-management
Self-management technologies provide patients with the information and tools that 
allow them to become active participants in their own care. Thus enabled, they can 
make healthy choices that improve control of blood sugar, blood pressure, and cho-
lesterol; and they can have more informed discussions with their clinicians. However, 
because self-management technologies only have an indirect effect on a clinician’s 
behavior, their influence on processes-of-care choices may be modest.
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Patient Participation: Participation in self-management would be low. Many patients 
would choose not to enroll or to drop out after enrollment.  
Care Process: When fully implemented, national adoption of self-management tech-
nologies would have no statistically significant impact on provider decisions to screen 
for retinopathy, neuropathy, or microalbuminuria. 
Physiology: When fully implemented, national adoption of self-management tech-
nologies would improve average:
•	 HbA1c	by	0.020	percent	
•	 Total	cholesterol	by	7.9	mg/dl.
It would have no impact on SBP.
Clinical Outcomes: Over the first ten years, national adoption of self-management 
technologies would cumulatively reduce:
•	 Heart	attacks	by	26,000
•	 Diabetes-related	mortality	by	170,000.
It would have no statistically significant effect on strokes, kidney failure, amputations, or 
blindness (at α=0.05).
Financial Outcomes: Over the first ten years, the national rollout of self-management 
technologies would result in:
•	 Implementation	costs	of	$16.2	billion
•	 Cost-of-care	savings	of	$285	million
•	 Overall	net	cost	of	$15.9	billion.
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Integrated Provider-Patient Systems
Integrated provider-patient systems would most fully achieve the envisioned benefits of 
diabetes management. They would help coordinate the efforts of all health care team 
members in delivering the best care possible, and they would provide patients with the 
tools to empower them in the management of their own health and to communicate 
effectively with their provider team (Table 3-1).
Patient Participation: We assumed that participation in integrated provider-patient 
systems would be high. The primary reason for non-participation would be the failure 
to identify eligible candidates.  
Care Process: When fully implemented, national adoption of provider-patient systems 
would improve average:
•	 Retinopathy	screening	from	14	percent	to	62	percent
•	 Peripheral	neuropathy	screening	from	45	percent	to	80	percent
•	 Microalbuminuria	screening	from	45	percent	to	66	percent.
Physiology: When fully implemented, national adoption of provider-patient systems 
would improve average:
•	 HbA1c	by	0.68	percent	
•	 SBP	by	4.2	mmHg
•	 Total	cholesterol	by	45	mg/dl.
Clinical Outcomes: Over the first ten years, national adoption of provider-patient 
systems would cumulatively reduce:
•	 Heart	attacks	by	160,000
•	 Strokes	by	16,000
•	 Kidney	failure	by	7,900
•	 Amputations	by	560,000
•	 Blindness	by	64,000
•	 Diabetes-related	mortality	by	920,000.
Financial Outcomes: Over the first ten years, the national rollout of provider-patient 
technologies would result in:
•	 Implementation	costs	of	$58.8	billion
•	 Cost-of-care	savings	of	$16.9	billion
•	 Overall	net	cost	of	$41.9	billion.
Chapter 3: Results
30 The Value of Information Technology-Enabled Diabetes Management
Overview of 10-year Results
 Payer
Provider Patient
Integrated 
System
Registries CDSS
Remote 
Monitor
Self 
Manage
Fi
na
nc
ia
l Care-Cost Savings 
($millions)
$7,100 $14,500 $10,700 $326 $285 $16,900 
System Cost ($millions) $21,600 $6,160 $19,300 $6,830 $16,200 $58,800 
Sc
re
en
in
g
Eye Exam   
(Baseline 14%)
25.60% 61.50% 23.50% 14.20% 14.20% 61.50%
Foot Exam  (Baseline 
45%)
57.80% 80.00% 67.50% 44.90% 44.90% 80.00%
Microalbuminuria    
(Baseline 45%)
52.60% 66.10% 61.40% 45.00% 45.00% 66.10%
Ph
ys
io
lo
gy
HbA1c (%) -0.24 -0.5 -0.28 -0.03 -0.02 -0.68
SBP (mmHg) -5.4 -1.1 4 -0.56 0 -4.2
Total Cholesterol (mg/dl) -11 -31 n/s -2.8 -7.9 -45
M
or
bi
di
ty
ESRD 3,000 5,600 2,600 n/s n/s 7,900
Amputation 190,000 560,000 340,000 n/s n/s 560,000
Blindness 18,000 63,000 20,000 n/s n/s 64,000
Cardiac Arrest &  
Heart Attack
54,000 100,000 -4,500 12,000 26,000 160,000
Stroke 19,000 5,200 -12,000 n/s n/s 16,000
M
or
ta
lit
y Absolute 
Improvement
380,000 710,000 210,000 270,000 170,000 920,000
Relative Improvement 1.90% 3.40% 1.00% 1.30% 0.83% 4.40%
n/s	denotes	lack	of	statistical	significance	at α=0.05.
Mortality and morbidity results presented as reduction in ten-year cumulative incidence.
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Net Benefit to Organizations
Because some forms of ITDM may achieve economies of scale, the overall net benefit 
picture may vary across organizations of different sizes.  Across all organizational sizes for 
payer technologies, remote monitoring and self-management, ITDM costs more than 
it saves.  Registries save more than they cost for all organizational sizes except single 
physician practices, and CDSS saves more than it costs for practices with greater than 
seven physicians (Table 3-2).  
Net Benefit by Organizational Size for Registries and CDSS
 CDSS Registries
1 MD -$346,000 -$17,000
2 MD -$293,000 $46,000
3 MD -$231,000 $120,000
4 MD -$154,000 $211,000
5-6 MD -$69,000 $312,000
7-9 MD $79,000 $494,000
10-15 MD $347,000 $816,000
16-25 MD $938,000 $1,530,000
26-49 MD $1,650,000 $2,360,000
50-75 MD $3,040,000 $4,080,000
76-99 MD $4,220,000 $5,580,000
100+ MD $17,000,000 $21,400,000
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Sensitivity Analysis and Stability Testing
One-way sensitivity analysis was performed against key variables: ITDM impact used 
by the ITDM Impacts Engine, patient-turnover rates used by the Population-Selection 
Engine, and discount rates used throughout the model. Across the range of ITDM 
impacts found in the literature, overall cost of care varied by up to 2.7 percent. Assuming 
a neutral effect on SBP by CDSS, cardiac complication rates improved by 2.1 percent, 
stroke rates improved by 0.56 percent, and an additional $1.2 billion cost-of-care savings 
was generated, for a total of $12 billion. Across a range of patient-turnover rates derived 
from the literature, cost of care varied by less than 4.0 percent. The discount rate was 
varied from 3.0 percent to 8.5 percent; cost of care increased by up to 14 percent and 
fell by up to 16 percent across this range. 
Additional Benefits
The diabetes-management literature reports additional benefits that may add substan-
tially to improved clinical and economic results projected by the model. For example, 
many programs incorporate smoking-cessation guidelines4 as part of their array of 
interventions.20,34,48,49  There is reason to believe not only that smoking cessation can 
improve health outcomes50 but also that patients with diabetes probably benefit more 
than those without.51
Similarly, diabetic guidelines often include recommendations for other processes of 
care, such as vaccinations,4,52,53 exercise, nutrition therapy, and weight loss.4  Diabetes 
management may improve compliance with these recommendations,20,29,54,55 which in 
turn may improve the health of patients with diabetes.51,56,57  
However, it was not possible to incorporate these additional improvements into the 
model.
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ITDM Improves Care
Our analysis demonstrates that all forms of ITDM improve processes of care, prevent 
development of diabetic complications, and generate cost-of-care savings. Technologies 
used by providers seem to be the most effective in improving the lives of patients with 
diabetes, and diabetes registries appear to be the most effective of all. Based upon the 
current evidence, our analysis indicates that patient-centered technologies offer the least 
potential for benefit. We believe that an integrated provider-patient platform, which 
adds patient-centered technologies to a registry and reminder system, would add ben-
efits beyond a registry alone.  This integrated platform would most fully achieve the 
envisioned benefits of diabetes management.
Cost Benefit Picture Varies by Technology
Not all forms of ITDM appear to be cost-beneficial. Diabetes registries are the only 
forms that are cost-beneficial in virtually all situations. CDSS is cost-beneficial only for 
larger provider organizations, and the remaining forms of ITDM are not cost-beneficial 
regardless of organizational size.
Cost Structure Varies Widely
The cost structures of the different technologies vary widely, and this has important 
implications on whether the associated programs can generate a net benefit. For 
example, remote monitoring and self-management technologies have large variable 
costs driven by the number of patients with diabetes who are managed. For self-
management technologies, the cost of interventions such as intense health coaching 
is based on a per-intervened-patient-per-month (PIPM) model. Large components 
of remote monitoring costs include the costs of associated devices and subscription 
fees for each patient. These variable costs prevent economies of scale from being real-
ized.  This lack of economies of scale, together with the smaller benefit achieved by 
these technologies, prevent these programs from being cost-beneficial, even for large 
organizations in our model.
Payer technologies are also not cost beneficial for organizations of any size in our model, 
despite the presence of economies of scale.  Larger payer organizations are often able 
to negotiate lower PIPM costs.  However, cost reductions due to increased negotiating 
leverage still do not allow large payer groups to achieve a positive net benefit in our 
model.  
Diabetes registries and CDSS achieve economies of scale because most costs are fixed, 
regardless of the number of patients managed. Benefits are highly dependant on the size 
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of the enterprise; each additional managed patient with diabetes brings the potential for 
added cost savings with little additional implementation cost. Thus these technologies 
become cost-beneficial for larger organizations.
Potential Benefit for Public Clinical Knowledge Repositories
The fixed costs associated with CDSS are the result of knowledge engineering tasks 
required to maintain clinical rules.  Clinical rule sets must be created and maintained 
in order for EMRs to appropriately trigger alerts, reminders and other forms of deci-
sion support.  If there were a publicly available national repository of relevant clinical 
knowledge, in such forms as alert and reminder logic, case finding definitions and report 
specifications, then a substantial cost would be lifted and the net benefit picture for 
CDSS might improve.
Market Inefficiencies May Foster Suboptimal Solutions
Because cost savings from improved care are largely reaped by payers, many diabetes-
management programs are implemented by payers rather than providers. Furthermore, 
providers have been slow to adopt health information technologies that underpin 
diabetes management programs.  Yet while implementation of payer technologies does 
improve the health of patients with diabetes and results in cost-of-care savings, providers 
are in the best position to improve care and control medical costs. This misalignment of 
incentives may be causing the market to pursue suboptimal interim solutions. 
Key Limitations
These results reflect the synthesis of best available evidence, expert opinion, and a 
detailed simulation model predicting financial and clinical impact. Further, our sensi-
tivity analyses have shown that the model is robust with respect to key variables. But 
although we believe these results to be the best estimate thus far of ITDM’s costs and 
benefits, a few key limitations should be noted.
Strength of Evidence
Estimates of the impact of diabetes management are limited by the strength of the 
underlying evidence, with two sets of assumptions deserving particular attention. First, 
because the best available evidence regarding the effect of CDSS-based diabetes man-
agement on SBP showed a detrimental effect, our model projects worsening blood-
pressure control with CDSSs. However, CDSSs in other settings show a neutral effect 
or improvement in blood-pressure control.58,59 Sensitivity analysis showed additional 
benefits, assuming a neutral effect on blood pressure; thus the model’s results may under-
estimate the true value of CDSSs. 
Second, the benefits of foot screenings may be overestimated. We were able to identify 
only one randomized controlled trial demonstrating the salutary effect of foot screening 
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on amputation rates.60 Because the care assumed in this study may not reflect standards 
of care throughout the country, it may overestimate the benefits of foot screening. 
Additionally, given the proprietary nature of cost information, it was difficult to obtain 
sufficient data to reflect the wide range of approaches currently found in diabetes man-
agement. Thus it was not possible to model the costs for all ways in which each type 
of technology is utilized in current practice. Based on interviews, extrapolation was 
required to project economies of scale and volume discounts. While we believe that all 
information shared in the interviews was accurate, the vendors could have under- or 
overestimated the costs of their program or product. Similarly, some of the practices, 
hospitals, and payers could have unintentionally omitted specific costs. Where possible, 
an unbiased third party reviewed the estimates.
Because of limited data, it was not possible to factor in the impact of organizational 
size in select cases. For example, estimates of CDSS costs in the model do not vary by 
organizational size. In reality, implementing an EMR modification in a large practice 
requires more time and planning to accommodate the requisite opinion leaders, while 
a smaller practice may implement a less customized set of guidelines to lower the 
cost. The impact of these size-specific considerations was not reflected in the model. 
Moreover, several other types of costs fall into this category. The cost of patient and 
provider	recruitment/marketing,	for	example,	was	excluded	because	it	varies	widely	by	
organizational size and particular program approach. 
Population under Analysis
Generally, organizations target different subsets of patients for different interventions. 
For example, patients more severely affected by diabetes may receive interventions that 
are more intense and more expensive.  Patients newly diagnosed with diabetes may 
receive more educational support.  Organizations may adopt predictive modeling efforts 
to more precisely target interventions to those who would benefit the most.  An analysis 
of such targeted approaches may change the net analysis.  However, inclusion of severity 
stratification and predictive modeling was not possible for this report.
Scope of Benefits
The complications included in the model are important causes of patient suffering and 
account for a substantial portion of health care dollars attributable to diabetes. However, 
patients with diabetes consume health care resources that are not accounted for in our 
model, and savings from decreased utilization from other sources is not captured. For 
example, decreased admissions from influenza, pneumonia, uncontrolled hyperglycemia, 
and other general medical conditions may account for a substantial amount of savings. 
The American Diabetes Association (ADA) estimates that such complications account 
for $44.1 billion, or roughly a third of total diabetic costs.3  Additionally, we did not 
model indirect costs—days lost from work, for example—though there is some evidence 
that such costs may be avoided through ITDM.61 The ADA estimates that indirect costs 
account for $40.8 billion, again a third of total diabetic costs. 
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We assumed that diabetes prevalence rates would not increase and included only diag-
nosed patients in our analysis. However, prevalence rates are likely to increase in the 
future as diabetic risk factors such as obesity become more prevalent.62,63   Further, the 
ADA estimates that of the 20.8 million patients with diabetes in this country, more than 
six million remain undiagnosed.2   Effective identification strategies within an overall 
disease-management program, with or without pre-diabetes components, might iden-
tify some of these undiagnosed patients. Whereas our model captures the incremental 
benefit of transitioning patients from existing levels of care to care under diabetes man-
agement, undiagnosed patients with diabetes represent potentially greater opportunities 
for improvement because they are currently untreated. 
Finally, the infrastructure for diabetes management might be leveraged for the man-
agement of other chronic diseases, such as congestive heart failure or asthma.  Where 
possible, such reuse might allow for additional benefits to be achieved without the full 
costs of starting a new disease management program from scratch.
Cross-Applicability of Studies
The evidence used in this analysis represents the best available data concerning the 
impacts of diabetes-management technologies on processes of care. However, applying 
estimates from one setting to projections in another can be hazardous. Diabetes-man-
agement programs show wide variation in a number of salient features, such as the 
programmatic elements included, the baseline quality of care, and the patient popula-
tion. For instance, remote-monitoring technologies are often targeted toward severe or 
difficult-to-control populations, but extrapolating that experience to all patients with 
diabetes nationwide may introduce error.
Our analysis projects the impact of ITDM when offered to all patients with Type 2 
diabetes in an organization or across the country. We include newly diagnosed or less 
severely affected patients with those at higher risk or who have already been affected 
by diabetic complications. Clearly, some of the newly diagnosed or less-severe patients 
may benefit from ITDM less than others. As a result, some organizations have adopted 
severity-stratification strategies or predictive modeling to target intervention to those 
patients with diabetes who may receive greatest benefit. This focusing of resources may 
yield a greater net benefit than is projected in our model.
Conclusion
While diabetes afflicts millions of Americans and can place a tremendous clinical and 
financial burden on our society, diabetes management offers an opportunity to improve 
care processes that enhance the lives of patients with diabetes and help control the med-
ical costs associated with their disease. However, current diabetes-management strategies 
are limited by a lack of well-conducted studies for determining their specific impacts 
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on costs and benefits. Our own study suggests that ITDM would improve the lives of 
patients with diabetes and generate cost savings if widely adopted, but it also suggests 
that misaligned incentives may cause the market to underutilize provider-based forms 
of ITDM. Ironically, these may be the most cost-beneficial approaches of all.
Chapter 4: Discussion

39
CITL Acknowledgments
This	 research	 was	 funded	 through	 the	 Robert	Wood	 Johnson	 Foundation,	 grant	
#049931. The Center for Information Technology Leadership (CITL), a research 
arm of Partners HealthCare, received unrestricted research support from the Health 
Information Management Systems Society over the time this research was conducted. 
Please refer to the CITL Web site (www.citl.org) for a full listing of past and current 
sponsors. None of the sponsors played a role in the design and conduct of the study; 
the collection, management, analysis, and interpretation of the data; or the preparation, 
review, and approval of the manuscript.
The authors acknowledge the members of our expert panel for their contributions. 
These expert panelists, excepting government employees, received nominal compensa-
tion for their time and efforts. The following individuals comprised the panel: Madhulika 
Agarwal,	MD,	MPH,	Veterans	Administration;	 Brian	Austin,	The	 Improving	Chronic	
Illness Care Program, MacColl Institute for Healthcare Innovations, Group Health 
Cooperative;	 Stephen	 J.	 Brown,	 Health	 Hero	 Network;	 Lawrence	 P.	 Casalino,	 MD,	
PhD,	University	of	Chicago;	Timothy	G.	Ferris,	MD,	MPH,	Partners/MGH	Institute	
for	Health	Policy,	Massachusetts	General	Hospital;	Jeremy	M.	Grimshaw,	MBChB,	PhD,	
FRCGP,	University	of	Ottawa;	Karen	M.	Kuntz,	ScD,	Harvard	School	of	Public	Health;	
John	A.	Merenich,	MD,	Kaiser	Permanente	Colorado;	and	David	Wennberg,	MD,	MPH,	
Health Dialog Data Services.
The authors would also like to acknowledge the Disease Management Association of 
America	and	Karen	Fitzner,	former	Director	of	Research	and	Program	Development,	
for	 their	help;	 and	Chris	Colonian	at	CIGNA,	 Jaan	Sidorov	at	Geisinger,	 and	David	
Wright at American Healthways for their assistance with the payer information. 
Additionally the authors would like to thank and acknowledge the following contribu-
tors: David Abelson, ParcNicollet; Michael Albisser, HumaLink; Doug Bach, Colorado 
Access; Bruce Barter, Centene Corporation; Susan Becker, Evanston Northwestern 
Healthcare; Heidi Bossley, AMA; Steve Brown, Health Hero; Wayne Burton, BankOne; 
Candy	Chitty,	Quality	First	Healthcare	Consulting,	Inc.;	Jim	Christian,	PHCC	LP;	Nicole	
Cook, HCNetwork; Steve Delaronde, Connecticare; Gretchen Flanders, Colorado Access; 
Jonah	Frohlich;	Adam	Habig	and	Teri	Wallace,	iSprit;	John	Haughom,	PeaceHealth;	John	
Haughton,	DocSite;	 John	Holland,	LifeLink;	Nancy	 Jarvis,	ParcNicollet;	Sharon	Katz,	
Mills	Peninsula	Medical	Group;	Vince	Kuraitis;	Stan	Lapidos,	Rush	University	Medical	
Center;	 John	Larsen,	Cerner	Corporation;	Diane	Lee,	MEDai;	Pat	Lierman,	Anthem;	
Kevin	 Maher,	 McKesson;	 David	 McCullough,	 GHC;	 Gretchen	 McGinnis;	 John	
Merenich,	 Kaiser;	 Lisa	Mohr,	 BCBS	 of	 SC/Companion	 Health;	Monica	 Neubauer,	
Acknowledgments
40 The Value of Information Technology-Enabled Diabetes Management
Medica;	Derek	Newell,	Lifemasters;	 Jeremy	Nobel,	Harvard	School	of	Public	Health;	
Gordon	Norman,	Pacificare;	Dr.	Gregory	Preston,	Keystone	Mercy	Health	Plan;	Doug	
Reagan, iMetrikus; Ed Rutherford, Teleminder; Chris Selecky, Lifemasters; Wells 
Shoemaker, PMG Santa Cruz; Skip Sievert, PHPMCS; Charlotte Silvers, Sid Peterson 
Memorial	 Hospital;	 Bob	 Stone,	 American	 Healthways;	 Mike	 Summers,	 McKesson;	
David	Teitelman,	 Pacificare;	Victor	Villagra,	 Health	 and	Technology	Vector;	 Sandeep	
Wadhwa,	McKesson;	and	Randy	Williams,	Pharos	Innovations.	
41
CITL Appendix 1: Literature Summary
Summaries of the articles used in our ITDM Impacts Engine can be found below. 
The selection of articles was based on study design strength and closeness of fit to the 
taxonomy.  The study findings presented below were either directly inputted into our 
model or served as the basis for calculated inputs. Preference was given to peer-reviewed 
literature.
Technologies Used by Payers
Newell and colleagues14 examined data of a LifeMasters program in a statewide health 
maintenance organization. The LifeMasters system compiled data from various sources 
(including remote-monitoring devices) and used algorithms to generate a customized 
intervention plan for staff to follow for each patient. One-page summaries for physi-
cians displayed trends in blood pressure, weight, and blood-glucose data together with 
LifeMasters notes from patient interactions. Among patients with diabetes in the pro-
gram for 12 months, average HbA1c decreased from 8.36 percent to 8.02 percent.64 
Data provided by the Geisinger Health Plan System’s disease management program15 
was analyzed and systolic blood pressure fell from 132.5 mmHg to 128.7 mmHg while 
LDL	cholesterol	levels	fell	from	114.0	mg/dl	to	104.6	mg/dl.65         
Rubin and colleagues17 compared the experiences of patients with diabetes in seven 
HMOs at baseline and after 6-14 months in a program run by Diabetes Treatment 
Centers of America. The company’s electronic tracking system included information 
about patient contacts, laboratory results, class attendance, hospital admissions, special-
ist visits, and ER use. Company staff worked both with patients and their physicians, 
sending reminders about screening and visits, supporting education, and providing nurse 
advocates. Screening rates for foot exams increased from 2 percent to 25 percent.
Villagra	 and	Ahmed	 compared	 baseline	 and	one-year	 intervention	 results	 in	 patients	
with diabetes enrolled in a disease-management program in 10 urban areas.16 A com-
pany software program included data from remote-monitoring devices and tracked 
patient progress. Patients had access to Web-based education and received phone calls 
from nurses as well as reminders and educational mailings. Annual dilated retinal exam 
rates increased from 40 percent in the baseline period to 48 percent in the follow-up 
period, and microalbuminuria screening rose from 27.3 percent to 37.3 percent.16 
Diabetes Registries
Montori, et al.20 reported that a diabetic electronic management system (DEMS) 
increased the frequency of microalbuminuria testing (27 percent to 55 percent), eye (36 
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percent to 69 percent) and foot (67 percent to 88 percent) exams and increased con-
trol of HbA1c levels, total cholesterol and blood pressure.  The DEMS was used by all 
persons on the care team, and the system included workflow tools specific to each role. 
It issued care prompts based on guidelines from the ADA and it also allowed clinicians 
to set patient goals.
Clinical Decision-Support Systems
Meigs and colleagues18 conducted a one-year randomized controlled trial to evaluate a 
Web-based diabetes “disease-management application” with interactive decision support. 
After opening the application, clinicians saw a single-screen view of diabetes-related 
information about the patient, including trended and tabular laboratory results, remind-
ers about routine exams, and specific treatment recommendations (e.g., “LDL exceeds 
goal of 100. Consider starting fluvastatin.”). The authors reported improved control of 
HbA1c levels, total cholesterol and blood pressure in the intervention group.  
In a six-month randomized controlled trial, Lobach and Hammond19 compared use 
of a diabetes-specific encounter form to a standard encounter form. An algorithm first 
compared the local clinicians’ version of ADA guidelines to information in the patient’s 
EMR, and it then produced a paper form showing the guidelines, recommendations, 
and due dates for the patient. Median guideline compliance for the clinicians receiving 
the recommendations was 32.0 percent, compared to 15.6 percent in the control group 
and included higher rates of eye, foot and microalbuminuria screening. 
Remote Monitoring
In	 a	 randomized	 controlled	 trial	 at	 the	Veterans	Affairs	 Boston	Health	Care	 System,	
McMahon, et al.21  monitored patients with diabetes at home through a Website that 
accepted uploads from a blood-pressure cuff and glucometer, offered access to educa-
tional modules and other Web-based diabetes resources, and facilitated online patient 
communication with a care manager. Based on glucose and hypertension treatment 
algorithms, the care manager provided recommendations to participants and primary-
care providers. After 12 months, average HbA1c fell from 9.5 percent to 8.6 percent, 
SBP	fell	10	mmHg	from	a	baseline	of	141	mmHg;	and	LDL	cholesterol	fell	6	mg/dl	
from	a	baseline	of	100	mg/dl.	Persistent	users	had	better	results.
Self-Management
In Glasgow and colleagues’ 10-month randomized trial,22 all patients had access to an 
Internet site with educational materials and a goal-setting dietary program. A subset of 
patients also had an online dietary coach they could access twice a week, and another 
subset participated in online discussions with other patients and received electronic 
newsletters.
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CITL Appendix 2: Intervention-Cost-Engine Estimates
All estimates for the intervention-cost engine are broken down into two categories, 
acquisition and annual. Acquisition costs are allocated to Year 1, whereas annual costs 
are incurred on an ongoing basis.
Payer Mediated Intervention Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
2 weeks of IT staff time to set up 
and run claims analysis to identify 
patients with diabetes
IT staff time for monthly refreshes 
of claims analysis to identify 
patients with diabetes
Program Implementation Fee One time fee: $125,000  None
Support Staff
Program manager, IT staff, and 
physician time to support the imple-
mentation of intervention
Program manager, IT staff, and 
physician time to support inter-
vention
Program Fee None
Per-intervened-member-per-
month fee varied by insurance 
type and organization size
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Registry with Reminders Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
2 weeks of IT staff time to set up 
and run claims analysis to identify 
patients with diabetes
IT staff time for monthly refreshes 
of claims analysis to identify 
patients with diabetes
Hardware Personal computer per physician: 
$500
5 year hardware replacement
Software None
Licensing fee for software and host-
ing services, includes IT support
Interfaces 3 interfaces: $10,000 each 17.5% of acquisition costs
IT Support Staff None None
Training
Vendor expenses plus physician 
and program manager time for 
training
Annual new employee training costs 
at 20% of acquisition costs
Non-IT Programmatic Costs None
Quarterly appointment reminder 
mailings: $4 per-intervened-mem-
ber-per-year fee
Modified EMR with Clinical Decision Support Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
None–patients with diabetes identi-
fied during clinical encounters by 
physicians
None
Hardware None–EHR is preexisting technology None
Software
200 hours of IT staff time to develop 
ED forms, flow sheets, referral 
forms, smart text and order sets, 
plus cost of standard reporting tool
20% of acquisition costs
Interfaces None– interfaces already exist None
IT Support Staff 10 hours of endocrinologist time to 
operationalize ADA guidelines
10 hours of endocrinologist time to 
update ADA guidelines
Training None–training occurs during initial 
EHR implementation
None
Non-IT Programmatic Costs None None
Table 
A-3
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Remote Monitoring Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
2 days of IT staff time to set up 
and run claims analysis to identify 
patients with diabetes
IT staff time for monthly refreshes 
of claims analysis to identify 
patients with diabetes
Hardware
Phone data transmission device  
for each patient: $100-$160; 
PC for each RN: $500
5 year hardware replacement
Software One time fee: $500-$1,500
Annual per patient fee ($25-$50) 
and per RN fee ($70-$90)
Interfaces 1 interface: $10,000 17.5% of acquisition costs
IT Support Staff None None
Training
Cost of 1 web-ex training session 
($250) and 8 hrs of RN time; Fee 
per RN for IT support ($12)
Fee per patient ($12); 20% of staff 
training acquisition costs for new 
staff
Non-IT Programmatic Costs None
Registered nurse time per 300 
patients with diabetes
Self Management Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
2 days of IT staff time to set up 
and run claims analysis to identify 
patients with diabetes
IT staff time for monthly refreshes 
of claims analysis
Hardware PC for each dietician: $500 5 year hardware replacement
Software One time fee: $500
Annual per patient fee ($70-$90) 
and per dietician fee ($70-$90)
Interfaces 1 interface: $10,000 17.5% of acquisition costs
IT Support Staff None None
Training
Cost of 1 web-ex training session 
($250-$300) and 8 hrs of dietician 
time; Fee per dietician for IT support 
($12)
$12 fee per patient; cost of web-ex 
training ($250-$300), hosting an 
average 150 patients; 20% of staff 
training acquisition costs for new 
staff
Non-IT Programmatic Costs None
Dietician time per 300 patients with 
diabetes
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Integrated Platform Acquisition and Annual Costs
Acquisition (Year 1 only) Annual (Years 1-10)
Identification
2 weeks of IT staff time to set up 
and run claims analysis to identify 
patients with diabetes
IT staff time for monthly refreshes 
of claims analysis to identify 
patients with diabetes
Hardware
PC for each dietician, nurse, and 
provider: $500 each; phone data 
transmission device for each patient: 
$100-$160 each, scaled by organi-
zation
5 year hardware replacement
Software One time fee: $500-$1,500
RM: Annual per patient fee ($25-
$50) and per RN fee ($70-$90)
SM: Annual license fee per patient 
($70-$90) and per dietician ($70-
$90)
Registry: Annual license and         
hosting fee for provider
Interfaces 3 interfaces: $10,000 each 17.5% of acquisition costs
IT Support Staff None None
Training
RM: Cost of 1 web-ex training ses-
sion ($250) and 8 hrs of RN time; 
$12 fee per RN for IT support $12 fee per patient;  cost of web-ex 
training ($250-$300), hosting an 
average 150 patients for combined 
self management and remote 
monitoring training; 20% of registry 
training acquisition costs for new 
staff training
SM: Cost of 1 web-ex training ses-
sion ($250-$300) and 8 hrs of dieti-
cian time; Fee per dietician for IT 
support ($12)
Registry: vendor expenses plus phy-
sician and program manager time 
for training
Non-IT Programmatic Costs None
SM: Dietician time per 300 patients 
with diabetes
RM: Registered nurse time per 300 
patients with diabetes
Registry: Quarterly appointment 
reminder mailings: $4 per-inter-
vened-member-per-year fee
Table 
A-6
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Madhulika Agarwal, MD, MPH, Acting Deputy Chief Officer of 
Patient Care Services, Veterans Health Administration
Dr. Agarwal is an internist who currently serves as the Deputy Chief Officer of Patient 
Care	Services	in	the	Veterans	Health	Administration’s	Office	of	Patient	Care	Services.	
In	this	capacity,	she	is	the	principal	advisor	to	the	VHA’s	Undersecretary	of	Health	on	
policy issues that relate to patient care and clinical services.
VHA	provides	health	care	to	more	than	5.1	million	veterans	and	7.6	million	enrollees	
throughout the United States. With a medical-care budget of approximately $30 bil-
lion,	VHA	directly	employs	more	than	196,500	health	care	professionals	at	more	than	
1,300 sites of care, including hospitals, community- and facility-based clinics, nursing 
homes, domiciliaries, readjustment counseling centers, and various other facilities. In 
addition	 to	 its	medical-care	mission,	VHA	is	 the	nation’s	 largest	provider	of	graduate	
medical education and a major contributor to medical and scientific research. More 
than 125,000 volunteers, 80,000 health profession trainees, and 25,000 affiliated medical 
faculty	are	an	integral	part	of	the	VHA	community.
Dr. Agarwal received her MD degree from Rajasthan University in India. She completed 
her	 training	 in	 internal	medicine	 at	 the	VA	Medical	Center–Georgetown	University	
program in Washington, D.C. She is a Diplomate of the American Board of Internal 
Medicine. She has also completed her Masters in Public Health at George Washington 
University in Washington, D.C.
Dr. Agarwal previously served as the Associate Chief of Staff for Ambulatory Care at 
the	VA	Medical	 Center,	Washington,	 D.C.,	 where	 she	 oversaw	 primary	 care,	 emer-
gency-room services, and the Community-Based Outpatient Clinics. She has also been 
involved in training medical students and residents as well as in health-services research. 
She holds a faculty appointment as Assistant Professor in the Department of Medicine 
at Georgetown University.
Brian Austin, Deputy Director, Improving Chronic Illness Care, and 
Associate Director, MacColl Institute for Health Care Innovation, 
Seattle
Mr. Austin is Deputy Director of Improving Chronic Illness Care (ICIC), a national 
program	of	the	Robert	Wood	Johnson	Foundation;	and	Associate	Director	of	the	Group	
Health Cooperative’s MacColl Institute for Health Care Innovation, which he helped 
found in 1992. The MacColl Institute is devoted to developing and disseminating inno-
vations in the delivery of health care, especially within a primary-care environment.
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Mr. Austin is also a co-developer of the Chronic Care Model, a systems approach for 
improving the delivery of care to the chronically ill, which MacColl has been testing 
and refining since the mid-1990s. The Model has been widely published and broadly 
adopted as an organizing framework, both nationally and internationally. Since 1998, 
the MacColl Institute has also served as the home for ICIC, for which Mr. Austin has 
been the lead administrator since its inception. He is also a member of the administra-
tive leadership team of the Group Health Cooperative’s Center for Health Studies (the 
Group Health Cooperative is the MacColl Institute’s parent). The Center conducts 
epidemiologic, health-services, behavioral, and clinical research addressing a wide and 
evolving range of clinical and public health questions.  
Stephen J. Brown, President and CEO, Health Hero Network, 
Redwood City, Calif. 
Mr. Brown is the founder of the Health Hero Network. During his leadership as CEO, 
the company has secured over $50 million in private financing to develop and com-
mercialize the Health Buddy® system, a technology platform that educates and moni-
tors patients at home and links them to chronic-care improvement services. The Health 
Hero Network is recognized as an industry-leading innovator and solution-provider 
in care management, with demonstrated and published outcomes showing quality 
improvement and cost-effectiveness for major health care institutions. Mr. Brown began 
his career by developing disease-management systems and software for pharmaceutical 
and medical-device companies while conducting research on interactive technologies 
for improving patient self-care and health-related behavior. Mr. Brown’s research has 
included some of the first interactive television and information-appliance applications 
for disease management, patient education, and behavioral health, resulting in over 50 
patents assigned to Health Hero Network. Mr. Brown graduated with a BS in Physics 
from Stanford University.
Lawrence P. Casalino, MD, PhD, Assistant Professor, University of 
Chicago
Dr. Casalino is a physician and health-services researcher at the University of Chicago. 
In addition to his 20 years as a family physician in private practice, he earned a PhD in 
health-services research, with a focus on organizational and institutional sociology and 
economics. He is a recipient of an Investigator Award in Health Policy Research from 
the	Robert	Wood	 Johnson	Foundation.	Dr.	Casalino	 conducts	 research	 in	 two	main	
areas: the effects of varying forms of organization on physician practice and the effects 
of	physician/hospital	and	physician/health-plan	relationships	on	the	quality	and	costs	of	
medical care. He also studies the ways in which public and private policies shape these 
forms and relationships. Among the journals in which his work has been published are 
the New England Journal of Medicine, the Journal of the American Medical Association, Health 
Affairs, Health Services Research, the Journal of Health and Social Behavior, and the Journal of 
Health Politics, Policy and Law.
49
Timothy G. Ferris, MD, MPH, Partners/MGH Institute for Health 
Policy, Massachusetts General Hospital, Boston
Dr.	Ferris	is	a	practicing	general	internist	and	pediatrician,	Vice	Chair	for	Quality	and	
Safety	for	Partners	Pediatrics,	and	a	senior	scientist	in	the	Partners/MGH	Institute	for	
Health Policy. He directs disease-management programs at Partners HealthCare, with 
specific responsibility for design, oversight, and evaluation of programs to improve 
quality and efficiency of care for high-risk patients such as those with heart failure. His 
research has focused on quality-improvement interventions for adults’ and children’s 
health care. In addition, he has studied the effects of the organization and financing 
on the costs and quality of care, risk adjustment of quality measures, and disparities in 
health care. Dr. Ferris has been a member of the Health Care Quality and Effectiveness 
Research study section of the Agency for Healthcare Research and Quality, and he has 
chaired two Technical Advisory Panels for the National Quality Forum. 
Jeremy Grimshaw, MBChB, Director, Centre for Best Practices, 
Institute of Population Health, University of Ottawa
Jeremy	 Grimshaw	 received	 an	 MBChB	 (MD	 equivalent)	 from	 the	 University	 of	
Edinburgh,	U.K.	He	trained	as	a	family	physician	prior	to	earning	a	PhD	in	health	ser-
vices research at the University of Aberdeen. He moved to Canada in 2002. His research 
focuses on the evaluation of interventions to disseminate and implement evidence-based 
practice. Dr. Grimshaw is Director of the Clinical Epidemiology Program at the Ottawa 
Health Research Institute; Director of the Centre for Best Practices at the University of 
Ottawa’s Institute of Population Health; Director of the Canadian Cochrane Network 
and	Centre;	 and	Tier	 1	 Canada	Research	Chair	 in	Health	 Knowledge	Transfer	 and	
Uptake. He is a full professor in the Department of Medicine, University of Ottawa, 
with a cross-appointment to the Faculty of Medicine’s Department of Epidemiology 
and Community Medicine.
Earlier, Dr. Grimshaw held a Personal Chair in Health Services Research at the University 
of	Aberdeen,	U.K.	and	was	the	Program	Director	of	the	Effective	Professional	Program	
within the Health Services Research—probably the largest research-implementation 
program	in	the	U.K.	Dr.	Grimshaw	has	established	a	comparable	program	in	Ottawa.	
He has a full registration with the General Medical Council and is member and Fellow 
of the Royal College of General Practitioners. 
Dr. Grimshaw’s research interests can be grouped according to three themes: system-
atic reviews of professional, organizational, financial, and regulatory interventions to 
improve professional and health care system performance; the design, conduct, and 
analysis of rigorous evaluations of dissemination and implementation strategies; and 
guideline-development methods.
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Karen M. Kuntz, ScD, Associate Professor, Harvard School of Public 
Health, Boston
Dr.	Kuntz	is	Associate	Professor	of	Decision	Science	in	the	Department	of	Health	Policy	
and Management at the Harvard School of Public Health. She is an internationally rec-
ognized decision analyst with extensive experience in the methods and applications of 
simulation modeling for evaluating clinical and public health strategies. She is currently 
principal investigator of one of the NCI-funded Cancer Intervention and Surveillance 
Modeling Network (CISNET) grants to evaluate national trends in colorectal can-
cer	incidence	and	mortality.	Dr.	Kuntz	has	become	one	of	the	leading	authorities	on	
describing errors and biases that can occur in disease modeling. She received her masters 
and doctorate, both in biostatistics, from the Harvard School of Public Health.
John A. Merenich, MD, Regional Director of the Colorado 
Permanente Care Management Institute (Chronic Disease 
Management Program), Colorado Permanente Medical Group, 
Denver
Dr. Merenich is a practicing physician and Regional Director of the Colorado 
Permanente	Care	Management	Institute	(CMI)	for	Kaiser	Permanente,	a	major	health	
care provider in Colorado. He supports CMI’s stated vision to “synthesize knowledge 
about the best clinical approaches and create, implement, and evaluate effective and 
efficient health care programs to improve the health of our members and community.” 
Or, stated more simply: “To make the right thing easier to do.”
Prior	to	joining	Kaiser	Permanente	Medical	Group,	Dr.	Merenich	completed	10	years	
of active duty with the U.S. Army. While at Fitzsimons Army Medical Center, he com-
pleted a fellowship and served as a research fellow in endocrinology and metabolism. 
Along with his current responsibilities at CMI, he is an Associate Professor of Medicine 
at the University of Colorado Health Science Center in Denver.
Dr. Merenich’s undergraduate training was in biology and he received his MD from 
Hahnemann University and Hospital, Philadelphia. He has published many articles and 
book chapters on topics that include evaluation of the role of drug therapy, cardiac risk, 
and lipid management in endocrine disorders. He is the recipient of several awards in 
recognition of his excellence in providing superior patient care.
David Wennberg, MD, MPH, President and COO, Health Dialog 
Analytic Solutions, Boston
Dr. Wennberg is President and Chief Operating Officer of Health Dialog Analytic 
Solutions and Director of the Center for Outcomes Research and Evaluation, Maine 
Medical Center. He graduated from the McGill University Faculty of Medicine in 1987. 
Dr. Wennberg’s post-graduate education was in internal medicine at the Maine Medical 
Center. Following his residency, he was a fellow in general internal medicine at the 
Harvard Combined Program and received an MPH from the Harvard School of Public 
51
Health. An internist with specialty training in health services and outcomes research, 
his major research interest is quality of care for cardiovascular services. Dr. Wennberg 
has worked with Health Dialog for six years, directing the company’s segmentation and 
analytic services for the Collaborative CareSM product line. In addition to helping found 
and run Health Dialog Analytic Solutions, he leads a nationally recognized research 
team at the Maine Medical Center, focusing on the drivers of utilization and quality in 
the delivery of health care services. 
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